Eckert & Ziegler BEBIG: Eckert & Ziegler buys Belgian provider of brachytherapy accessories

Press Release

Regulated information

28 August 2016, 06:00 p.m.

Seneffe, August 28, 2016. Eckert & Ziegler BEBIG SA took over 100 % of the shares in BrachySolutions BVBA effective August 26, 2016. The company, which is based in Leuven, Belgium, is one of the largest independent European distributors of prostate seeds. Its main markets are Benelux and Portugal. Both parties have agreed not to disclose the purchase price.

Through the takeover, Eckert & Ziegler is acquiring BrachySolutions' customer base in Benelux, the United Kingdom, and Portugal, thereby securing its strong position in Europe as a manufacturer of seeds. BrachySolutions generated 1.1 Million Euro sales in 2015 resulting in EBIT of 0.2 Million Euro for the period. Preliminary numbers for 2016 are in the same magnitude like numbers in the same period in 2015. Eckert & Ziegler Bebig will integrate this revenue stream in its current business. Next to the current earnings of BrachySolutions, it is expected that additional earnings will be generated, due to the extended value chain within the group. The net debt position as well as the number of employees of Eckert & Ziegler BEBIG Group will not change materially due to this transaction.

"By acquiring BrachySolutions, we are further honing our strategic focus. Our strategy centers on consolidating the market, cementing our market position in Europe, and creating synergies within our portfolio of solutions," said Dr. Harald Hasselmann, Managing Director of Eckert & Ziegler BEBIG and member of the Board of Directors.

"Eckert & Ziegler's Berlin-made prostate implants stand for top quality. I believe firmly that our brachytherapy customers will continue to receive the best possible products and excellent service in the future," Luk Herremans, founder and Managing Director of BrachySolutions, added.

Brachytherapy is a medical treatment method that includes placing implants containing radioisotopes directly into tumor tissue. The local radiation provided by the implants leads to the destruction of cancer cells. Permanent brachytherapy is mainly used to treat prostate cancer.  

About Eckert & Ziegler BEBIG

Eckert & Ziegler BEBIG is a European-based group active in the medical device segment of the health care industry. Its core business is the treatment of cancer using brachytherapy, a special form of radiation therapy. Eckert & Ziegler BEBIG is a leader in brachytherapy in Europe. The company headquarters are in Belgium, with a production facility in Germany and subsidiaries throughout Europe, in the USA, India and Brazil. In addition, Eckert & Ziegler BEBIG has a worldwide network of distributors and agents to support the international marketing of its product line. The company's products and equipment are intended for use by oncologists, radiologists, urologists and medical physicists. Eckert & Ziegler BEBIG group employs more than 120 people. The company has been listed on the Euronext stock exchange since April 1997.

Contact:
Eckert & Ziegler BEBIG SA
Investor Relations
Tel.: +32 (0) 64 520 808
E-mail: ir@bebig.com